Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Will Arbutus Biopharma (ABUS) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation ABUS. The stock has moved higher by 35% in the past month, while it is also above its 20 Day SMA. This combination of strong price performance and favorable technicals suggest that the stock may be on the right path.

We certainly think so, particularly if you consider ABUS’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.